- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01372982
Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions
June 13, 2011 updated by: Dr. Reddy's Laboratories Limited
An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) Of Dr.Reddy's Laboratories Ltd And Femara 2.5 mg Tablets (Reference) Of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fed Conditions
The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fed conditions.
Study Overview
Detailed Description
An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative oral bioavailability study in healthy, post menopausal women subjects under fed conditions.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 69 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
Healthy post menopausal women within the age range of 40 to 69 years.
- A body mass index within 18-29.9 Kg/m2
- The postmenopausal status should be confirmed by
- Serum Estradiol concentration < 40 pg/mL.
- Serum follicle stimulating hormone FSH)concentration >30 IU/L.
- No vaginal bleeding for at least 1 year.
- Given written informed consent to participate in the study.
- Absence of disease markers ofHIV 1 & 2, hepatitis B & C virus and RPR. Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history and physical examination during the screening.
- A normal l2-lead ECG.
- A normal chest X-ray (PA view) with in six months before the date of dosing.
- Comprehension of the nature and purpose of the study and compliance with the requirement of the entire protocol.
- No history or no evidence of hypersensitivity/ idiosyncratic reaction to Letrozole and related drugs or peanut products or other ingredients of the Letrozole formulation.
- No history of significant systemic diseases.
- Non-smokers.
- No history of psychiatric disorders.
- No donation of blood (one unit or 350 mL) within 56 days prior to study check- in.
- No history of addiction to any recreational drug or drug dependence.
- No participation in any clinical study within the past 56 days.
- No receipt of any prescription drugs within 4 weeks or over-the-counter drugs (e.g.: Cold preparations, and antacid preparations vitamins and natural products used for therapeutic benefits) within 14 days prior to receiving the first dose of study medication or repeated use of drugs within the last four weeks.
- No history of dehydration from diarrhoea, vomiting or any other reason within a period of 24 hours prior to study check-in.
- No family history of neurological disorders.
- Not consumed alcohol and xanthine containing food and beverages, (chocolates, tea, coffee or cola drinks) cigarettes and tobacco products, for at least 48 hours, prior to study check in.
- Not consumed grape fruit containing food or beverages (mosumbi/sweet lime) or poppy containing foods within the 7 days prior to check-in of both periods.
- Negative results for drugs of abuse (Benzodiazepines, Cocaines, Opioids, Amphetamines,Cannabinoids and Barbiturates) in urine during the each period of study check-in.
- Negative alcohol breathe analysis during the each period of study check-in.
Exclusion Criteria:
Subjects incapable of understanding the informed consent.
- History of suggestive of breast carcinoma, endometrial carcinoma or cervical carcinoma.
- History of suggestive of deep vein thrombosis and / or undiagnosed vaginal bleeding.
- History of thromboembolic disorders.
- History of seizures.
- History of any other major surgical procedure in the past 3 months.
- History of diabetes mellitus and systemic hypertension.
- Past history of anaphylaxis or angioedema.
- History of porphyria, Dubin-Johnson, Rotor syndrome or any other hyperbilirubinemia syndrome.
- History of otosclerosis exacerbated during pregnancy.
- History of cardiovascular, renal, hepatic, ophthalmic,pulmonary, neurological, metabolic,haematological, gastrointestinal,endocrine or immunological diseases.
- Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study {one drink is equal to one unit of alcohol [one glass wine, half pint beer, and one measure (one ounce) of spirit}.
- History of difficulty with donating blood or difficulty in accessibility of veins.
- An unusual or abnormal diet e.g. low sodium diet, for two weeks prior to receiving any medication and through out subject's participation in the study, for whatever reason e.g. because of fasting due to religious reasons.
- Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
- If any Dysplastic changes in the Papanicolaou Smear.
- Female volunteers demonstrating a positive pregnancy test.
- Female volunteers who are currently breast-feeding.
- History of problem in swallowing tablet.
- Used an oral contraceptive containing estrogens or progesterone, or any form of hormonal therapy or intake of HRT and pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 6 months of the start of the study.
- History of habituation to coffee, tea or other xanthine containing products and inability to withhold the intake during the-in house-stay.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Letrozole
|
Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
Other Names:
|
Active Comparator: Femara
|
Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioavailability based on Cmax and AUC parameters
Time Frame: 3 Months
|
3 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: A. Jaya Chandra Reddy, FRCS, Trident Life Sciences Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
June 1, 2008
Study Completion (Actual)
June 1, 2008
Study Registration Dates
First Submitted
June 13, 2011
First Submitted That Met QC Criteria
June 13, 2011
First Posted (Estimate)
June 14, 2011
Study Record Updates
Last Update Posted (Estimate)
June 14, 2011
Last Update Submitted That Met QC Criteria
June 13, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Malnutrition
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
Other Study ID Numbers
- 033/08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Letrozole
-
Helsinki University Central HospitalFoundation for Paediatric Research, FinlandCompletedConstitutional Delay of Growth and PubertyFinland
-
Rovi Pharmaceuticals LaboratoriesRecruiting
-
Institut du Cancer de Montpellier - Val d'AurelleNovartisCompleted
-
University of Alabama at BirminghamGenentech, Inc.; Breast Cancer Research FoundationCompletedBreast Cancer | Breast Neoplasm | Cancer of the BreastUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedBreast Neoplasms
-
IVI MadridActive, not recruitingLuteinised Follicular CystSpain
-
Fudan UniversityRecruitingEndometrial CancerChina
-
Assiut UniversityRecruitingInfertility, FemaleEgypt
-
Cairo UniversityAhmed Elgazzar HospitalCompleted
-
Genor Biopharma Co., Ltd.Recruiting